OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 10,131 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 10,131 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total value of $234,026.10. Following the completion of the sale, the director owned 6,526,633 shares in the company, valued at $150,765,222.30. The trade was a 0.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

OrthoPediatrics Stock Down 1.3%

Shares of NASDAQ:KIDS opened at $23.00 on Wednesday. The stock has a fifty day simple moving average of $21.61 and a two-hundred day simple moving average of $18.76. The stock has a market capitalization of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. On average, research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its holdings in OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares in the last quarter. Legal & General Group Plc bought a new position in OrthoPediatrics during the 2nd quarter valued at about $34,000. Northwestern Mutual Wealth Management Co. lifted its stake in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares during the period. Caption Management LLC purchased a new stake in shares of OrthoPediatrics during the 3rd quarter valued at about $54,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KIDS. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research lifted their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Finally, Needham & Company LLC raised their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.